Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Department of Laboratory of Pathology, Nagasaki University Hospital, Nagasaki, Japan.
Respir Investig. 2021 May;59(3):335-341. doi: 10.1016/j.resinv.2020.12.008. Epub 2021 Feb 4.
The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function; however, predicting changes in lung function is difficult. We sought to determine whether the prior 6-month trend in forced vital capacity (FVC) could predict mortality and the subsequent 6-month trend in FVC.
We retrospectively analyzed consecutive patients with newly diagnosed IPF who underwent serial pulmonary function tests. The immediate two years after the initial evaluation were divided into four terms of six months each and stratified on the basis of presence or absence of a ≥10% relative decline in FVC at six months (declined and stable groups, respectively).
We included 107 patients with %predicted FVC of 80.8% and %predicted diffusing capacity of the lung for carbon monoxide of 58.9%. In multivariate analysis, a decline in %predicted FVC in the initial six months was found to be an independent prognostic factor (hazard ratio 4.45, 95% confidence interval 2.62-7.56, p < 0.01). Among the 46 terms in which the FVC declined during the initial 1.5-year study period, a decline in FVC was exhibited in 23 (50.0%) of the subsequent terms. Among 231 terms in which FVC remained stable, a decline was observed in 32 (13.9%) of the subsequent terms (relative risk 3.61, p < 0.01). The frequency of FVC decline in each term was 16-27%. FVC was stable or declined in all four terms in 50.5% and 15.9% of cases, respectively.
Six-month decline in FVC predicts subsequent FVC change and mortality in IPF patients in the era of antifibrotic agents.
特发性肺纤维化(IPF)的临床病程表现为肺功能逐渐下降;然而,预测肺功能变化具有一定难度。我们旨在确定 FVC(用力肺活量)在过去 6 个月的变化趋势是否可以预测死亡率和随后 6 个月的 FVC 变化趋势。
我们回顾性分析了连续诊断为 IPF 并接受了系列肺功能检测的患者。初始评估后的两年内,每 6 个月分为 4 个时间段,并根据 FVC 在 6 个月时是否下降≥10%(分别为下降组和稳定组)进行分层。
我们纳入了 107 名 FVC%预计值为 80.8%和一氧化碳弥散量%预计值为 58.9%的患者。多变量分析显示,最初 6 个月 FVC%预计值下降是独立的预后因素(危险比 4.45,95%置信区间 2.62-7.56,p<0.01)。在最初 1.5 年的研究期间,46 个时间段中有 46 个 FVC 下降,其中 23 个(50.0%)随后的时间段中 FVC 仍持续下降。在 231 个 FVC 稳定的时间段中,有 32 个(13.9%)随后的时间段中 FVC 下降(相对风险 3.61,p<0.01)。每个时间段 FVC 下降的频率为 16-27%。在所有四个时间段中,50.5%的患者 FVC 稳定或下降,15.9%的患者 FVC 持续下降。
在抗纤维化药物时代,FVC 在过去 6 个月的下降预示着 IPF 患者随后的 FVC 变化和死亡率。